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THE HAPLOIMMUNOSTORM SYNDROME: A DISTINCT CLINICAL ENTITY
SEEN IN HLA-MISMATCHED CELLULAR IMMUNOTHERAPY
Colvin, G.A.1; Rathore, R.1; Lum, L.G.1; Abedi, M.1; Ballen, K.K.2;
Dey, B.R.2; Elfenbein, G.J.1; Quesenberry, P.J.1 1. Roger Williams
Medical Center, Adele R. Decof Cancer Center, and The Department of
Research, Providence, RI; 2. Massachusetts General Hospital, Boston,
MA.
We have observed a new infusion related clinical entity named
haploimmunostorm (HIS), observed after minimal immunosup-
pressive HLA-3/6 or 4/6 mismatched stem cell transplantation.
We have performed a total of 44 HLA-mismatched transplants
with escalation of the CD3 dose from 1  106-2  108 cells/kg
using G-CSF primed PBSC, with a conditioning regimen of 100
cGy TBI. The CD34 dose was 2  106 cells/kg. This post-
infusion HIS syndrome occurred in 26 out of 30 (87%) patients
with a CD3 dose more than 1  108 cells/kg. In the HIS
syndrome, a constellation of symptoms occurred, some with vari-
able penetrance, in which hyperpyrexia and malaise were a constant
feature occurring as early as four hours after cell infusion with a
median time of 14-hours. A morbilliform rash was seen in 40% of
patients. Biopsies of these rashes revealed no evidence of hyper-
acute or acute graft versus host disease; rather epidermal spongiosis
with lymphocytic invasion was usually seen. Diarrhea was present
in a smaller subpopulation of patients (20%) and biopsies taken of
the colon also failed to show any evidence of acute graft versus host
disease. Transient elevations of liver enzymes occurred in 40% of
the patients within 6–24 hours after infusion. Hematologic mani-
festations consisted of marked lymphopenia, which began at the
time of initial hyperpyrexia. Steroids were used successfully if the
HIS syndrome lasted more than 72 hrs. Preliminary cytokine level
analysis showed variable increases of serum TNF-alpha and IL-2
post bone marrow transplantation compared with pre-transplant
levels. Complete cytokine level analysis is ongoing. This syndrome
is believed to be immunologically based and represents neither
hyperacute nor acute graft versus host disease. This syndrome is
different than an engraftment syndrome reported in some patients
undergoing autologous hematopoietic stem cell transplant, partic-
ularly patients with breast cancer. Engraftment syndrome occurs at
the time of engraftment, opposed to HIS in which there is transient
chimerism lasting on average a week after cell infusion. Engraft-
ment syndrome is similar to HIS in that it is associated with fever
and rash but deviates with presence of capillary leak and pulmonary
inﬁltrates.
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EVALUATION OF THE STRUCTURAL BASIS OF T CELL ALLORECOGNI-
TION USING RECOMBINANT HLA CLASS I MULTIMERS
Oosten, L.E.M.1; Whitelegg, A.2; Jordan, S.2; Madrigal, A.J.2;
Goulmy, E.1; Barber, L.D.2 1. Leiden University Medical Center,
Leiden, The Netherlands; 2. The Anthony Nolan Research Institute,
London, United Kingdom.
Graft-versus-Host disease is a major complication of any stem
cell transplant that uses stem cells from an HLA-mismatched
donor. However, these transplants may also possess potential for
beneﬁcial non-self HLA restricted responses to tumor antigens.
Manipulation of these alloreactivities requires information on the
structural basis of T cell allorecognition. In the CD8 T cell
response to allogeneic HLA class I molecules both peptide-inde-
pendent and peptide-speciﬁc recognition have been suggested to
play a role. We examined peptide-speciﬁc allorecognition using
A*0201 tetramers representing ﬁve self-peptides known to bind
endogenously to HLA-A*0201. Small numbers of CD8 T cells
speciﬁc for these self-peptides were detected within four in vitro
stimulated T cell populations speciﬁc for allogeneic HLA-A*0201.
Peptide-independent allorecognition was investigated using artiﬁ-
cial antigen presenting constructs (aAPCs) comprising latex beads
coated with single A*0201/peptide complexes, CD54 and CD80.
The aAPCs stimulated production of IFN- by T cells speciﬁc for
the A*0201/peptide complex on the bead-surface. None of the four
T cell populations speciﬁc for allogeneic HLA-A*0201 were stim-
ulated by aAPCs whereas they did produce IFN- when stimulated
with cells naturally expressing HLA-A*0201. The results indicate
that alloreactive populations comprise subsets of T cells speciﬁc for
self-peptides presented by non-self HLA class I molecules with no
evidence of a peptide independent component.
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SILENCING HUMAN NKG2D, DAP10 AND DAP12 REDUCES CYTOTOX-
ICITY OF IN VIVO ACTIVATED CD8 T AND NK CELLS
Karami, M.A.; Cao, T.M.; Baker, J.; Verneris, M.R.; Negrin, R.S.
Stanford University, Stanford, CA.
NKG2D is a cell surface receptor expressed on NK cells, CD8
T cells,  T cells. NKG2D is activated by stress-induced ligands
MICA and MICB, and UL16 binding proteins which are expressed
on target cells modiﬁed by infection, or stress. Binding of NKG2D
on NK cells results in an activation signal that bypasses or over-
rides inhibitory signals from major histocompatibility complex
(MHC) I resulting in cytotoxic granule content release and target
cell killing. Signaling is achieved by selective expression of the
adaptor proteins DAP10 and DAP12. We have shown that CD8
T cells activated with IFN-, anti CD3 mAb and IL2 express
NKG2D and share functional and phenotypic properties with NK
cells. Activated CD8 T cells up-regulate NKG2D as well as
DAP10 and DAP12 during ex-vivo activation and expansion which
correlates with cytotoxic function. To further elucidate the role of
NKG2D signaling in CD8 T cell-mediated cytotoxicity, 21-
nucleotide small interfering RNAs (siRNA) were designed the
NKG2D gene. FACS analysis, northern and western blots dem-
onstrated that effector cells transfected with siRNA incorporated
into the pLV ThM lentiviral vector resulted in 90% suppression
of NKG2D expression after 72 hrs. In both CD8 T cells and NK
cells, suppression of NKG2D resulted in a 90% decrease in
cytotoxicity against tumor cell line targets (RPMI and U266). We
also performed experiments using an autologous tumor targets
derived from ascites. Similar to the results obtained using CD8 T
cells and NK cells against target cell lines, suppressing NKG2D
expression in activated CD8 T Cells resulted in 90% decrease
in cytotoxicity against the autologous tumor targets. To character-
ize the role of DAP10 and DAP12 in NKG2D cytotoxic signaling,
we generated siRNA spanning DAP10 and siRNA for DAP12.
Using northern blot analysis, 90% suppression of DAP 10 and
DAP12 was observed when CD8 T cells and NK cells were
treated with the siRNA. Suppression of DAP10 expression in
CD8 T cells and NK cells resulted in a decrease in cytotoxicity of
more than 75% compared to control cells. Suppressing DAP12
expression also resulted in signiﬁcant reduction in cytotoxicity,
however was consistently less than that of DAP10. When DAP10
and DAP12 were simultaneously silenced in CD8 T and NK
cells, an 82% reduction in cytotoxicity was observed. These that
both DAP12 and DAP12 are involved in activated and expanded
CD8 T cell cytotoxicity.
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CD6-DEPLETED MOBILIZED STEM CELLS FOR MODIFICATION OF HVG
AND GVH REACTIONS AFTER HLA-HAPLOIDENTICAL MARROW TRANS-
PLANTATION
Kolb, H.-J.1; Bigalke, I.2; Simoes, B.3; Falk, C.2; Tischer, J.1; Hill, W.1;
Ledderose, G.1 1. Hematopoietic Cell Transplantation, Department of
Medicine III, University of Munich, Munich, Bayern, Germany; 2.
Institute of Molecular Immunology, GSF-National Research Centre for
Environment and Health, Munich, Bayern, Germany; 3. Medical School
University of Sao Paulo-Ribeirao Preto, Ribeirao Preto, Sao Paulo,
Brazil.
Allogeneic stem cell transplantation is limited to patients with a
histocompatible donor, but for patients with advanced acute leu-
kemia and high-grade lymphoma HLA-haploidentical transplan-
tation may be considered. Rejection of the transplant and graft-
versus-host disease are major obstacles and T-cell depletion
eliminates the graft-versus-leukemia effect and causes prolonged
immune deﬁciency. Here we studied the use of CD6-depleted
G-CSF mobilized blood cells (mbc) 6 days after transplantation of
unmodiﬁed marrow in order to suppress host-versus-graft and
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graft-versus-host reactions (GVHD) retaining a graft-versus-leu-
kemia effect and the capacity to reconstitute the immune system.
CD6-depleted mbc contain a large proportion of NK and NK-T
cells. 63 patients with advanced disease (AML 32, ALL 15, NHL
11, CLL 2, CML 2, SAA 1) were transplanted with marrow from
family donors sharing one HLA-haplotype and differing in 0–4
HLA-antigens of the second haplotype. Conditioning consisted of
total body irradiation (TBI), antithymocyte globulin (ATG) and
cyclophosphamide (CY), post-grafting immunosuppression of cy-
closporin A (CSA) and a short course of methotrexate (sMTX). A
transfusion of donor leukocytes was given prior to CY. Complete
engraftment was observed in 34 evaluable patients given 12 Gy
TBI. The dose of TBI could be reduced to 4 Gy without rejection
in 25 evaluable patients. GVHD was severe (grade III and IV) in 12
of 48 evaluable patients. An improved method of CD6-depletion
was administered to mbc in 9 patients and severe GVHD did not
develop. GVHD responded to corticosteroids in most patients. 15
patients survive disease free up to 6 years (median 784 days).
Recurrent infections including PTLD were the major cause of
transplant-related mortality. Absolute counts of lymphocytes, CD4
and CD8 subpopulations were not different from those of a con-
temporary group of 46 patients in advanced disease given HLA-
identical sibling transplants. However naı¨ve CD4 cells and TRECs
were low. Rejection, GVHD and GVL have been controlled by
this regimen, but immune reconstitution remains a problem that
may be solved by early discontinuation of immunosuppression in
this regimen.
GVH/GVL
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ACUTE GRAFT VERSUS HOST DISEASE AFTER NON-MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION (NST) WITH LOW-DOSE
TBI, FLUDARABINE AND ANTITHYMOCYTE GLOBULIN (ATG)
Grosskreutz, C.L.; Scigliano, E.; Fruchtman, S.M.; Isola, L.M. Hema-
tology-Oncology Division, Mount Siani Medical Center, New York, NY.
Acute GvHD is a frequent complication of NST although at a
lower rate and severity than after full myeloablation. ATG given
with conditioning produces substantial host immunosuppression
and is thought to produce T-cell depletion of the allograft. We
previously showed that the addition of ATG to TBI 200 cGy and
ﬂudarabine can improve donor engraftment. Whether it impacts
on acute and chronic GvHD and on graft versus tumor effect is less
known. Forty-seven pts, not eligible for conventional allogeneic
SCT, underwent NST using ATG 15 mg/kg/day (equine) or 1.5
mg/kg/day (rabbit) days 4 to 1, single fraction TBI 200 cGy day
5, ﬂudarabine 30 mg/kg/day days4 to2. Oral MMF and CSA
started on day 5. Allografts were G-CSF mobilized PBSC.
Thirty-two pts (68%) had match related donors, 9 (19%) match
unrelated (10/10), 1 (2%) mismatch related (9/10) and 5 (10.6%)
mismatch unrelated donors (9/10). Twenty-ﬁve pts had sex
matched donors (53.2%). Full donor chimerism was documented
in 85% and partial (50%) in 11% of pts. At a median follow up
of 309 days, GvHD grade II-IV developed in 13 pts (27.6%). Fatal
GvHD of liver and/or gut occurred in 8 pts (17%). The mean age
of pts who developed GvHD was 54 years and 57 for those who did
not (p  ns). The corresponding mean ages for their donors were
47 vs. 50 years (p  ns). Seven out of fourteen (50%) unrelated
transplants recipients and 6/33 (18%) with related donors devel-
oped GvHD (p  0.023). Infectious complications were seen in 8
pts (17%) and were the cause of death in 6 (12%). Thirteen of the
47 pts (27.6%) underwent transplant for AML. Six pts had re-
lapsed/refractory disease at the time of transplant. 3 were in CR2
and 4 in CR1. Eleven pts (84.6%) relapsed with AML after trans-
plant. Previously reported data on NST using 200 cGy of TBI and
ﬂudarabine with no ATG showed an incidence of acute GvHD
grade II-IV of 64% and 24% GvHD related mortality. Similar
rates have been reported with ﬂudarabine and melphalan reduced-
intensity conditioning. In our cohort of 47 pts the addition of ATG
resulted in decreased incidence of acute GvHD grade II-IV and
GvHD related morality without a high rate of infectious compli-
cations. A high incidence of disease relapse in pts with AML may
reﬂect the high proportion of pts with advanced leukemia enrolled
in the study. However, it also warrants further investigation to rule
out that ATG may hinder graft versus leukemia effect.
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SENSITIVE AND QUANTITATIVE CHIMERISM ANALYSIS IN ALL PA-
TIENTS WITH REAL-TIME PCR
Uzunel, M.1; Ulf, S.1; Jonas, M.2; Petter, S.2; Marie, S.1; Dan, H.1;
Olle, R.2 1. Clinical Immunology F79, Stockholm, Sweden; 2. Center for
Allogeneic Stem Cell Transplantation, Stockholm, Sweden.
In this study, we wanted to evaluate the predictive value of a
sensitive chimerism method for relapse in 45 patients with acute
lymphoblastic leukemia (ALL) after allogeneic stem cell transplan-
tation (SCT). The method, based on real-time PCR using single
nucleotide polymorphic (SNP) markers, was shown to be more
than one log more sensitive than the most common used methods.
Mixed chimerism (MC) was detected in the peripheral blood (PB)
and bone marrow (BM) samples of all patients that relapsed. How-
ever, a high degree of MC was also found in patients without
relapse (57% MC in PB and 94% MC in BM). In some patients
still in remission, MC was found 4–5 years after SCT. In paired
BM-PB samples, the level of recipient cells were more than one log
higher in BM as compared to PB. Chimerism results after 3
months post-SCT were associated with relapse. In PB samples,
13/15 patients with a MC level of 0.1% relapsed as compared to
3/22 patients below this level (p
0.001). The median time be-
tween ﬁrst detection of this level and relapse was 5.5 (range 0.3–44)
months. In BM samples, 10/15 patients with a MC level 1%
relapsed as compared to 1/11 patients below this level (p
0.01).
The median time between ﬁrst detection of this level and relapse
was 18 (1.8–34) months. In conclusion, using a new sensitive
chimerism method, a high incidence of MC was found after SCT.
Despite this, threshold levels associated with relapse were found
both in PB and BM. The time period between ﬁrst detection of
these levels and relapse may be long enough for immunotherapeu-
tic interventions to have an antileukemic effect.
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CLINICAL RELEVANCE OF RECIPIENT LEUKOCYTE INFUSION (RLI)
THERAPY
Saito, T.I.; Sykes, M. Transplantation Biology Research Center, Mas-
sachusetts General Hospital/Harvard Medical School, Boston, MA.
Background: Surprisingly, anti-tumor responses can occur in
patients who reject donor grafts following nonmyeloablative he-
matopoietic cell transplantation (Dey et al., Biol Blood Marrow
Transplant 7:604). In murine mixed chimeras prepared with non-
myeloablative conditioning, we previously showed that recipient
leukocyte infusions (RLI) induced anti-tumor responses against
host-type tumors (Rubio et al. Blood 102:2300). To further inves-
tigate the clinical relevance of this RLI model, we 1. evaluated the
effect of RLI from tumor-bearing mice and 2. compared RLI with
allogeneic lymphocyte infusion in untreated mice. Methods:
Mixed chimerism was achieved in BALB/c (H-2d) mice condi-
tioned with depleting anti-CD4 and CD8 mAbs on Day 5,
cyclophosphamide 200 mg/kg on Day 1 and 7 Gy thymic irra-
diation on Day 0 prior to transplantation of 25  106 B10.BR
(H-2k) bone marrow cells. Some groups received RLI (3  107
BALB/c spleen cells) seven weeks post-BMT. Some RLI donor
mice received BALB/c A20 B cell lymphoma cells (1  105) two
weeks before RLI. Some groups received RLI depleted of B cells
by MACS column for purging tumor cells. A20 cells (5 105) were
given i.v. one week after RLI in chimeras or after allogeneic
lymphocyte infusion (3  107 B10.BR spleen cells) to untreated
BALB/c mice. Results: In the clinical setting, RLI would be
obtained from tumor-bearing hosts. We therefore examined
whether RLI is still effective when the lymphocytes are obtained
from tumor-bearing mice. Recipients of RLI from tumor-bearing
mice showed similar tumor survival compared to recipients of RLI
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